In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Turnstone Biologics closes $11.3mm Series A

Executive Summary

Turnstone Biologics Inc. (developing oncolytic virus-based therapies for cancer) raised $11.3mm through its Series A round led by Versant Ventures. Founding investor FACIT (Fight Against Cancer Innovation Trust; established by the Ontario Institute for Cancer Research) also participated. Versant takes two board seats.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Vaccines
Deal Status
  • Final
Deal Type
  • Financing
    • Private Placement

Related Companies